| Full Name |
HIV Type O Envelope (Synthetic), Human Immunodeficiency Virus Antigen, Recombinant
|
Abbreviated Name-1 |
HIV type-O envelope (synthetic); |
| Documents |
|---|
| Figures |
|---|
| Reference |
|---|
Kottilil S, et al. Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J. Immunol. Jan 2006; 176(2): 1107-1114.
Barbouche R, et al. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. J. Biol. Chem. Jan 2003; 278(5): 3131-3136.
|
|
Description |
GenScript Human Immunodeficiency Virus (HIV) Type O Envelope (synthetic), containing the HIV type-O transmembrane envelope-derived specific sequence. Detects all clades of HIV type-O infected individuals responding to HIV-type O envelope proteins. |
Purity |
Peptide is >95% pure As determined by HPLC-C18, and MASS Analysis. |
Storage |
Reagent is shipped at ambient temperature. Freeze upon arrival. Store at -20°C. |
Concentration |
1 mg/ml in H2O. |
Stability |
Five years frozen. One month in solution at 4°C. |
Specificity |
Immunoreactive with all sera of HIV type-O infected individuals. |
Applications |
Antigen in Rapid Tests, ELISA and Western blots. |
Note |
; |
